A

Adverum Biotechnologies
D

ADVM

2.45000
USD
0.00
(0.00%)
مفتوح الان
حجم التداول
2,133
الربح لكل سهم
-6
العائد الربحي
-
P/E
-0
حجم السوق
51,182,296
أصول ذات صلة
A
ABEO
-0.16500
(-2.68%)
5.99500 USD
ALNY
ALNY
1.49
(0.48%)
309.49 USD
A
ARWR
-0.120
(-0.76%)
15.630 USD
C
CRSP
0.330
(0.80%)
41.690 USD
E
EDIT
0.20500
(10.43%)
2.17000 USD
R
RCKT
-0.05500
(-1.87%)
2.88000 USD
REGN
REGN
-2.17
(-0.41%)
527.22 USD
S
SRPT
-15.750
(-43.54%)
20.420 USD
V
VYGR
0.01500
(0.46%)
3.31000 USD
المزيد
الأخبار المقالات

العنوان: Adverum Biotechnologies

القطاع: Healthcare
الصناعة: Biotechnology
Adverum Biotechnologies Inc is a clinical-stage company that aims to establish gene therapy as a new standard of care for prevalent ocular diseases. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. Its product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable therapeutic levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with bolus anti-vascular endothelial growth factor (VEGF) IVT injections.